New drug aims to cut blood transfusions for MDS patients

NCT ID NCT07422480

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This Phase 3 trial compares elritercept to epoetin alfa in 300 adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who need red blood cell transfusions. The main goal is to see if elritercept can help patients go without transfusions for at least 12 weeks while raising hemoglobin levels. The study also looks at quality of life and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: elritercept (also called TAK-226) and epoetin alfa
What this could lead to: If elritercept works better than epoetin alfa, it could offer a new option to reduce or avoid blood transfusions for people with MDS-related anemia.
What could go wrong: This is an early-stage Phase 3 trial with 300 participants, so results may not apply to everyone. Elritercept may not prove more effective or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Male or female participants aged ≥ 18 years or older at time of signing the informed consent form (ICF). 2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF prior to any trial-related procedures being conducted and authorization to use protected health information and personal data in accordance to national and local privacy regulations. 3. Documented diagnosis of myelodysplastic syndrome(s) (MDS) according to WHO 2016 classification that meets International Prognostic Scoring System - Revised (IPSS-R) classification of very low-, low-, or intermediate-risk disease, confirmed by central laboratory independent reviewer prior to randomization. Hemoglobin (Hgb), platelet, and absolute neutrophil count (ANC) values should be collected greater than (\>) 14 days after red blood cell (RBC) transfusion or greater than (\>) 7 days after platelet transfusion, unless otherwise considered to be pretransfusion values. 4. Bone marrow less than (\<) 5% blasts in an evaluable bone marrow collected at screening and confirmed by central pathology independent reviewer. 5. Endogenous serum erythropoietin s (EPO) level of \<500 U/L. Should be results from blood samples collected \>14 days following an RBC transfusion to evaluate for eligibility unless considered pretransfusion values. 6. Participant requires RBC transfusion, as documented by the following criteria. A transfusion requirement of 2 to 6 pRBCs units/8 weeks confirmed for a minimum of 8 weeks immediately preceding randomization. • Hgb levels at the time of or within 3 days prior to administration of a RBC transfusion must have been less than or equal to (≤) 9.0 grams per deciliter (g/dL) (5.6 millimoles per liter (mmol/L)) with symptoms of anemia (or ≤7 g/dL \[4.3 mmol/L\] in the absence of symptoms) in order for the transfusion to be counted towards meeting eligibility criteria. • RBC transfusions administered when hemoglobin (Hgb) levels were \>9.0 g/dL (or \>7 g/dL in the absence of symptoms) and/or RBC transfusions administered for elective surgery, infections or bleeding events will not qualify as a required transfusion for the purpose of meeting eligibility criteria or stratification. 7. Hgb \<11.0 g/dL (6.8 mmol/L) after last RBC transfusion preceding randomization. Local laboratory is acceptable to facilitate randomization. 8. Eastern Cooperative Oncology Group score of 0, 1, or 2. Exclusion Criteria  1. Prior therapy with any of the following: 1. Epoetin alfa • At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 2 doses of only epoetin alfa ≥8 weeks prior to randomization. No other erythropoiesis-stimulating agent (ESA) agent is allowed. 2. Darbepoetin 3. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor administered ≤8 weeks (56 days) prior to randomization unless given for treatment of febrile neutropenia. 4. Immunomodulatory drug (IMiDs) including lenalidomide • At the investigator's discretion in consultation with the medical monitor may be allowed if received ≤1 week of an IMiD ≥8 weeks prior to randomization. 5. Hypomethylating agent • At the investigator's discretion, in consultation with the medical monitor may be allowed if received no more than 2 doses ≥8 weeks prior to randomization. 6. Luspatercept, sotatercept, imetelstat, or elritercept 7. Immunosuppressive therapy 8. Hematopoeitic cell transplant 9. Iron chelation if administered ≤8 weeks prior to randomization. Participants on stable doses of iron chelation therapy for ≥8 weeks are allowed Vitamin B12 or folate therapy initiated within 4 weeks prior to randomization. Participants on stable replacement doses for ≥4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed. 10. Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed 11. High-dose corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone ≤10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed. Other disease modifying treatments for autoimmune diseases may be allowed upon medical monitor review. 12. Investigational agent or any other agent intended for treatment MDS treatment 2. Diagnosed to have MDS associated with del(5q) cytogenetic abnormality or MDS unclassifiable according to WHO 2016 classification or secondary MDS. 3. Known history of diagnosis of acute myeloid leukemia (AML). 4. Anemia due to any other known cause including but not limited to thalassemia; hypothyroidism; due to iron, vitamin B12, vitamin B6, zinc, or folate deficiencies; autoimmune or hereditary hemolytic anemia; any type of known clinically significant bleeding or sequestration or drug induced anemia, hemolytic anemia, or bleeding events. 5. Clinically significant cardiovascular disease defined as: 1. New York Heart Association heart disease class III or IV 2. Fridericia corrected QT (QTcF) interval \>500 milliseconds during screening 3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening 6. Known ejection fraction \<35%, confirmed by a local echocardiogram performed during screening, or a previously performed echocardiogram if collected within 6 months before screening. 7. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (DVT; including proximal and distal), pulmonary or arterial embolism, arterial thrombosis or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed. 8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimeters of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment. 9. Prior history of malignancies, other than MDS. Participants who are free of other malignant disease for ≥3 years and have completed treatment, including maintenance are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy: 1. Basal or squamous cell carcinoma of the skin; 2. Carcinoma in situ of the cervix; 3. Carcinoma in situ of the breast; 4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] clinical staging system). 10. History of solid organ or bone marrow transplantation. 11. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 14 days before randomization. 12. Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines. 13. Body mass index ≥ 40 kilograms per square meter (kg/m\^2). 14. Major surgery within 28 days before randomization. 15. New-onset seizures or poorly controlled seizures within 12 weeks prior to randomization are excluded from trial participation. 16. History of allergy/anaphylaxis to investigational product (including epoetin alfa) excipients (refer to the current elritercept investigator's brochure for a list of excipients) or recombination proteins. 17. History of pure red cell aplasia and/or antibody against erythropoietin (EPO). 18. Any of the following laboratory abnormalities: 1. ANC \<500/microliter (μL) (0.5×109/L). 2. Platelet count \<50,000/μL (50×109/L) or ≥450,000/μL (450×109/L). 3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3× upper limit of the normal (ULN). 4. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin \<3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review. 5. Estimated glomerular filtration rate \<30 mL/min/1.73 m\^2 as determined by the Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration equation. 6. Ferritin ≤50 micrograms per liter (μg/L). 7. Folate ≤2.0 nanograms per milliliter (ng/mL). 8. Vitamin B12 ≤200 picograms per milliliter (pg/mL). 19. Ongoing participation in another interventional clinical trial. 20. Participant is unwilling or in the opinion of the investigator the participant is unable to comply with the requirements of the protocol. 21. Is a participant of childbearing potential (POCBP) but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of trial intervention. 22. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom during the entire trial intervention period until at least 60 days after the last dose of trial intervention. 23. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire trial intervention period until at least 60 days after the last dose of trial intervention. 24. For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Myelodysplastic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

The study's own enquiry address

This study publishes an address for enquiries. See it below .
The places running it

162 sites in 28 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AIMS, Kochi
NOT_YET_RECRUITING

Kochi, Kerala, 682041, India
AZ Delta (H.-Hartziekenhuis Roeselare-Menen vzw (HHRM)) - Campus Rumbeke
NOT_YET_RECRUITING

Roeselare, West Flanders, 8800, Belgium
AidPort
RECRUITING

Skorzewo, Wielkopolska, 60185, Poland
Albert Einstein College - Montefiore
RECRUITING

The Bronx, New York, 10467, United States
Alfred Hospital
NOT_YET_RECRUITING

Richmond, Victoria, 3004, Australia
American Oncology Partners P.A. MidAmerica Cancer Care
RECRUITING

Kansas City, Missouri, 64132, United States
Amsterdam UMC-Locatie VUMC (Vrije Universiteit Medisch Centrum)
RECRUITING

Amsterdam, North Holland, 1081HV, Netherlands
Ankara Universitesi, TAp FakAltesi, Hematoloji BD
NOT_YET_RECRUITING

Ankara, Ankara, Turkey, 06520, Turkey (Türkiye)
Apollo Hospital Hyderabad
NOT_YET_RECRUITING

Hyderabad, Telangana, 500096, India
Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi - Istituto di Ematologia "Lorenzo e Ariosto Seragnoli"
NOT_YET_RECRUITING

Bologna, 40138, Italy
BRCR Medical Center Inc
RECRUITING

Tamarac, Florida, 33321, United States
Banner MD Anderson Cancer Center
NOT_YET_RECRUITING

Gilbert, Arizona, 85234, United States
Banphaeo General Hospital
NOT_YET_RECRUITING

Ban Phaeo, Samutsakorn, 74120, Thailand
Calvary Mater Newcastle
NOT_YET_RECRUITING

Waratah, New South Wales, 2282, Australia
Cancer & Blood Research Center
NOT_YET_RECRUITING

Whittier, California, 90270, United States
Centre Hospitalier Universitaire (CHU) de Nice - Hopital L'Archet I - Hematologie Clinique
RECRUITING

Nice, 06200, France
Centre Hospitalier Universitaire Grenoble Alpes
NOT_YET_RECRUITING

La Tronche, Isere, 38700, France
Centro de Hematologia e Oncologia (CHO)
NOT_YET_RECRUITING

Joinville, Santa Catarina, 89201-260, Brazil
Centro de Investigacion Clinica Chapultepec (CICC), S.A. de C.V
NOT_YET_RECRUITING

Morelia, Michoacán, 58260, Mexico
Chang Bing Show Chwan Memorial Hospital
RECRUITING

Changhua, 505029, Taiwan
Charite Campus Benjamin Franklin
RECRUITING

Berlin, 12200, Germany
China Medical University Hospital
RECRUITING

Taichung, TW, 404, Taiwan
Christian Medical College
NOT_YET_RECRUITING

Vellore, Tamil Nadu, 632517, India
Chu-Ucl Namur Site Godinne
RECRUITING

Yvoir, Namur, 5530, Belgium
Chugoku Central Hospital
RECRUITING

Fukuyama-shi, Hiroshima, 720-0001, Japan
Churchill Hospital
NOT_YET_RECRUITING

Oxford, OXON, OX3 7LE, United Kingdom
City of Hope - Comprehensive Cancer Center (CCC)
NOT_YET_RECRUITING

Duarte, California, 91010, United States
Cleveland clinic OH
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Cork University Hospital
RECRUITING

Cork, T12 DC4A, Ireland
D'OR Institute for Research and Education
NOT_YET_RECRUITING

Salvador, Estado de Bahia, 41253-190, Brazil
Democritus University of Thrace (DUTH) - University General Hospital of Alexandroupolis
NOT_YET_RECRUITING

Alexandroupoli, Evros, 68100, Greece
Dokkyo Medical University Hospital
RECRUITING

Mibu, Tochigi, 321-0293, Japan
Dr. Pencho Georgiev - Outpatient Center for Individual Practice for Specialized Medical Care in Internal Medicine and Clinical Hematology (EOOD)
RECRUITING

Plovdiv, 4000, Bulgaria
Eastern Haematology & Oncology Group or Austin Hospital
NOT_YET_RECRUITING

Heidelberg, Victoria, 3084, Australia
Ege University Medical Faculty
NOT_YET_RECRUITING

Izmir, 35100, Turkey (Türkiye)
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Epic Medical Research
NOT_YET_RECRUITING

Monroe, Louisiana, 71201, United States
Epic Medical Research - Shreveport
NOT_YET_RECRUITING

Shreveport, Louisiana, 71106, United States
Faculty of Medicine, School of Health Sciences, University of Ioannina
NOT_YET_RECRUITING

Ioannina, 45500, Greece
Filantropia Municipal Clinical Hospital
NOT_YET_RECRUITING

Craiova, Dolj, 20014, Romania
Fiona Stanley Hospital
NOT_YET_RECRUITING

Perth, Western Australia, 6150, Australia
Flinders Medical Centre
NOT_YET_RECRUITING

Bedford Park, South Australia, 5042, Australia
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Fukushima Medical University Hospital
RECRUITING

Fukushima, Fukushima, Japan, 960-1295, Japan
Gemeinschaftspraxis fuer Haematologie und Onkologie - Praxis Steinfurter Strasse
RECRUITING

Münster, North Rhine-Westphalia, 48153, Germany
General Hospital of Thessaloniki "Ippokratio"
NOT_YET_RECRUITING

Thessaloniki, Macedonia, 55133, Greece
Gifu Municipal Hospital
RECRUITING

Gifu, Gifu, 500-8323, Japan
Gruppo Humanitas-Humanitas Research Hospital (Istituto Clinico Humanitas)
NOT_YET_RECRUITING

Rozzano, Milan, 20089, Italy
Gustave Roussy
NOT_YET_RECRUITING

Villejuif, X, 94805, France
Helse Bergen HF
RECRUITING

Bergen, Vest, 5021, Norway
Hematology Oncology Associates of Rockland
NOT_YET_RECRUITING

Nyack, New York, 10960, United States
Hospital 9 de Julho (Rede Americas/DASA)
NOT_YET_RECRUITING

São Paulo, 01409-000, Brazil
Hospital Amaral Carvalho (HAC)
NOT_YET_RECRUITING

Jaú, São Paulo, 17210080, Brazil
Hospital Mae de Deus, Clinical Research Unit - Cancer Institute
NOT_YET_RECRUITING

Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
Hospital Privado de Cordoba
NOT_YET_RECRUITING

Córdoba, X5000, Argentina
Hospital Sultanah Aminah Johor Bahru (HSAJB)
RECRUITING

Johor Bahru, Johor, 80100, Malaysia
Hospital Sultanah Bahiyah (HSB) (Klinik Kesihatan Bandar Alor Setar/Hospital Alor Setar)
RECRUITING

Alor Star, Kedah, 11450, Malaysia
Hospital Universitari Vall d'Hebron-Institut de Recerca (VHIR)
NOT_YET_RECRUITING

Barcelona, 8035, Spain
Hospital Universitario Virgen de la Victoria (HUVV)
RECRUITING

Málaga, 29010, Spain
Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)
NOT_YET_RECRUITING

Seville, Seville, 41013, Spain
Hospital of Lithuania University of Health Sciences Kaunas, Clinic of Oncology and Hematology
RECRUITING

Kaunas, LT, 50161, Lithuania
Huntsman Cancer Institute
NOT_YET_RECRUITING

Salt Lake City, Utah, 84124, United States
Hyogo Prefectural Amagasaki General Medical Center
RECRUITING

Amagasaki-shi, Hyōgo, 660-8550, Japan
IRCCS Ospedale San Raffaele
NOT_YET_RECRUITING

Milan, 20132, Italy
Insel Gruppe AG
NOT_YET_RECRUITING

Bern, 3010, Switzerland
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals Location
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Institute of Cancer Research and Treatment of Candiolo
RECRUITING

Candiolo, Torino, 10060, Italy
Instituto Medico de la Fundacion Estudios Clinicos
NOT_YET_RECRUITING

Rosario, Santa Fe Province, 2000, Argentina
Institutul Oncologic Prof. Dr. I. Chiricu
RECRUITING

Cluj-Napoca, Cluj, 400124, Romania
Irmandade da Santa Casa da Misericordia de Santos (ISCMS)
NOT_YET_RECRUITING

Santos, São Paulo, 11075-101, Brazil
Istanbul Florence Nightingale Hospital
NOT_YET_RECRUITING

Istanbul, 34381, Turkey (Türkiye)
Kantonsspital Graubunden
NOT_YET_RECRUITING

Chur, Kanton Graubünden, 7000, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITING

Kaohsiung City, 807, Taiwan
King Chulalongkorn Memorial Hospital
NOT_YET_RECRUITING

Bangkok, 10330, Thailand
King's College Hospital
RECRUITING

London, SE5 9RS, United Kingdom
Korea University Anam Hospital
NOT_YET_RECRUITING

Seoul, 02841, South Korea
LUMI Research
RECRUITING

Houston, Texas, 77090, United States
Laiko General Hospital
NOT_YET_RECRUITING

Athens, Central Athens, 11526, Greece
Maharaj Nakorn Chiangmai Hospital
NOT_YET_RECRUITING

Chiang Mai, Chiang Mai, 50200, Thailand
Mater Misericordiae University Hospital
NOT_YET_RECRUITING

Dublin, Dublin 7, Ireland
Max SuperSpeciality Saket, Delhi
NOT_YET_RECRUITING

Delhi, 110017, India
Mersin Medicalpark Hospital
NOT_YET_RECRUITING

Mersin, Mezitli, 33000, Turkey (Türkiye)
Mid North Coast Local Health District - Mid North Coast Cancer Institute (MNCCI) - Coffs Harbour
NOT_YET_RECRUITING

Coffs Harbour, New South Wales, 2450, Australia
Moffitt Cancer Center
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
Monash University-Monash Medical Centre (MMC) - Clayton
NOT_YET_RECRUITING

Clayton, Victoria, 3168, Australia
NHO Nagoya Medical Center
RECRUITING

Nagoya, Aichi-ken, 460-0001, Japan
NTT Medical Center Tokyo
RECRUITING

Shinagawa-ku, Tokyo, 141-8625, Japan
National Cheng Kung University Hospital
RECRUITING

Tainan, 704, Taiwan
National Institute of Medical Sciences and Nutrition Salvado
NOT_YET_RECRUITING

Mexico City, 14080, Mexico
National Taiwan University Hospital - East Campus
RECRUITING

Taipei, 100225, Taiwan
National and Kapodistrian University of Athens (NKUA)-Laiko General Hospital
NOT_YET_RECRUITING

Athens, Central Athens, 11527, Greece
National and Kapodistrian University of Athens-University General Hospital Attikon
NOT_YET_RECRUITING

Athens, West Athens, 12462, Greece
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40207, United States
Novant Health Care Institute
NOT_YET_RECRUITING

Winston-Salem, North Carolina, 27106, United States
Oaxaca Site Management Organization S.C. - Oaxaca
NOT_YET_RECRUITING

Oaxaca City, 68000, Mexico
Ondokuz Mayis University School of Medicine, Department of Hematology
NOT_YET_RECRUITING

Samsun, Atakum, 55139, Turkey (Türkiye)
Orchard Healthcare Research Inc. (OHR) - Skokie
RECRUITING

Skokie, Illinois, 60077, United States
Oslo Universitetssykehus HF
NOT_YET_RECRUITING

Oslo, 0372, Norway
Ospedale Cardarelli
NOT_YET_RECRUITING

Naples, 80131, Italy
Ospedale di Novara
RECRUITING

Novara, 28100, Italy
Pilgrim Hospital
RECRUITING

Boston, Lincolnshire, PE227BU, United Kingdom
Poitiers University Hospital Center - Miletrie Site
RECRUITING

Poitiers, Vienne, 86021, France
Policlinico Umberto I
NOT_YET_RECRUITING

Roma, Rome, 00161, Italy
Polyclinic San Matteo, IRCCS, Department of Oncohematology, Operative Unit of Hematology
NOT_YET_RECRUITING

Pavia, PV, 27100, Italy
Porto Alegre Clinical Hospital (HCPA)
NOT_YET_RECRUITING

Porto Alegre, Rio Grande do Sul, 90035903, Brazil
Portuguese Charity of Sao Paulo, Clinical Hematology / Oncology Center
NOT_YET_RECRUITING

São Paulo, 01321-001, Brazil
Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh
NOT_YET_RECRUITING

Chandigarh, 160012, India
Pratia MCM Krakow
NOT_YET_RECRUITING

Krakow, maAopolska, 50-727, Poland
Pratia Onkologia Katowice
RECRUITING

Katowice, Silesian Voivodeship, 40-519, Poland
Pratia Wroclaw
RECRUITING

Wroclaw, Lower Silesian Voivodeship, 50-019, Poland
Praxis am Volkspark
RECRUITING

Berlin, 10715, Germany
Providence Medical Group
NOT_YET_RECRUITING

Santa Rosa, California, 95403, United States
Queen Elizabeth Hospital Birmingham
NOT_YET_RECRUITING

Birmingham, West Midlands, B15 2TH, United Kingdom
Renovatio Clinical
NOT_YET_RECRUITING

The Woodlands, Texas, 77380, United States
Royal Adelaide Hospital
NOT_YET_RECRUITING

Adelaide, South Australia, 5000, Australia
Sahyadri Hospitals, Pune
NOT_YET_RECRUITING

Pune, Maharashtra, 411004, India
Saint-Louis Hospital
NOT_YET_RECRUITING

Paris, 75010, France
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Sanatorio Allende S.A. - Nueva Cordoba
NOT_YET_RECRUITING

Córdoba, 5000, Argentina
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Soon Chun Hyang University Hospital Seoul
RECRUITING

Seoul, Yongsan-gu, 04401, South Korea
South Eastern Sydney Local Health District
NOT_YET_RECRUITING

Sydney, New South Wales, 2217, Australia
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Clinic of Hematology
RECRUITING

Sofia, 1756, Bulgaria
St. James's Hospital
NOT_YET_RECRUITING

Dublin, 091 524411, Ireland
St. Vincent's Hospital Melbourne
NOT_YET_RECRUITING

Fitzroy, Victoria, 3065, Australia
Swiss Medical Center - Barrio Parque
NOT_YET_RECRUITING

Buenos Aires, 1425, Argentina
Sykehuset Vestfold HF
RECRUITING

Tønsberg, Vestfold, 3116, Norway
Szent Borbala Korhaz, Department of Internal Medicine and Haematology, Division of Hematology
RECRUITING

Tatabánya, Komárom-Esztergom, 2800, Hungary
Taipei Veterans General Hospital
NOT_YET_RECRUITING

Taipei, 112201, Taiwan
Tata Medical Center, Kolkata
NOT_YET_RECRUITING

Kochi, Kerala, 682041, India
Tennessee Oncology, PLLC
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology - Denton
NOT_YET_RECRUITING

Denton, Texas, 76201, United States
The Cancer and Hematology Centers
NOT_YET_RECRUITING

Grand Rapids, Michigan, 49503, United States
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITING

Seoul, 06591, South Korea
The Center for Cancer and Blood Disorders
RECRUITING

Fort Worth, Texas, 76104, United States
The Christie NHS Foundation Trust
NOT_YET_RECRUITING

Manchester, M20 4BX, United Kingdom
The University of Texas-MD Anderson Cancer Center - Leukemia Center
RECRUITING

Houston, Texas, 77030, United States
Thomas Jefferson University
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
RECRUITING

Bunkyo-ku, Tokyo, 113-8677, Japan
UZ Leuven
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
Universidad Autonoma de Nuevo Leon-Hospital Universitario "Dr. Jose Eleuterio Gonzalez" - Servicio de Hematologia
NOT_YET_RECRUITING

Monterrey, Nuevo León, 64460, Mexico
Universidad de Salamanca - Hospital Universitario de Salamanca
RECRUITING

Salamanca, 37007, Spain
Universita Degli Studi di Roma "Tor Vergata"
NOT_YET_RECRUITING

Rome, 00133, Italy
Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC)
NOT_YET_RECRUITING

Florence, Florence, 50141, Italy
Universita degli Studi di Padova-Azienda Ospedaliera di Padova
NOT_YET_RECRUITING

Padua, 35128, Italy
Universitatsklinikum Bayreuth, Med. Klinik IV
RECRUITING

Bayreuth, Bavaria, 95445, Germany
Universitatsspital Zurich
NOT_YET_RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland
Universiti Malaya - Faculty of Medicine (FOM)
RECRUITING

Kuala Lumpur, Kuala Lumpur, 59200, Malaysia
University Hospital Galway
NOT_YET_RECRUITING

Galway, H91 YR71, Ireland
University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
NOT_YET_RECRUITING

Halle, Saxony-Anhalt, 06120, Germany
University Hospital Ramon y Cajal
NOT_YET_RECRUITING

Madrid, 28034, Spain
University Hospitals of Leicester NHS Trust
NOT_YET_RECRUITING

Leicester, Leicestershire, LE1 5WW, United Kingdom
University and Polytechnic Hospital La Fe
RECRUITING

Valencia, 46026, Spain
University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology
RECRUITING

Debrecen, H-B, 500096, Hungary
University of Miami
NOT_YET_RECRUITING

Miami, Florida, 33136, United States
Vilniaus Universiteto Ligonine Santaros Klinikos (VULSK) (Vilniaus Universiteto Ligonines Santariskiu Klinikos)
NOT_YET_RECRUITING

Vilnius, 08661, Lithuania
Virginia Commonwealth University (VCU)-Medical Center - North Hospital
NOT_YET_RECRUITING

Richmond, Virginia, 23298, United States
Warszawski Uniwersytet Medyczny (WUM) (Medical University of Warsaw)
RECRUITING

Warsaw, Masovian Voivodeship, 02-172, Poland
West Virginia University Cancer Institute
NOT_YET_RECRUITING

Wheeling, West Virginia, 26003, United States
World Research Link
RECRUITING

Baytown, Texas, 77521, United States
Yale
NOT_YET_RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.